ANVISA Opens Fast-Track for Chinese Rehab Devices in Brazil

On May 7, 2026, Brazil’s National Health Surveillance Agency (ANVISA) issued Resolution RDC No. 45/2026, establishing an expedited regulatory pathway for certain Chinese-made rehabilitation devices—including electric wheelchairs and smart walking aids. The move shortens the registration timeline from 180 days to 45 working days for products compliant with both IEC 60601-2-52 and GB 9706.1-2020 standards. This development is especially relevant for medical device exporters, manufacturers of mobility aids, and regulatory affairs professionals operating in or targeting the Latin American market.

Event Overview

On May 7, 2026, ANVISA published Resolution RDC No. 45/2026. The resolution introduces a special approval channel for rehabilitation devices manufactured in China. Eligible products must meet dual conformity: IEC 60601-2-52 (international standard for medical electrical equipment — particular requirements for rehabilitation equipment) and GB 9706.1-2020 (Chinese general safety standard for medical electrical equipment). Under this mechanism, the regulatory review period is reduced from 180 days to 45 working days. Initial authorizations have been granted to six manufacturers based in Guangdong and Jiangsu provinces.

Industries Affected

Direct Exporters of Medical Devices

Exporters shipping electric wheelchairs or smart walking aids from China to Brazil are directly impacted because the shortened timeline lowers time-to-market barriers. The change affects not only application preparation but also commercial planning cycles—particularly for firms previously constrained by ANVISA’s standard review duration.

Manufacturers of Mobility and Rehabilitation Equipment

Manufacturers—especially those in Guangdong and Jiangsu already authorized under the new pathway—face immediate implications for production scheduling, labeling compliance, and post-market documentation. Their ability to align internal quality systems with both IEC and GB standards becomes a prerequisite for eligibility, not just a certification option.

Regulatory Affairs and Compliance Service Providers

Firms offering ANVISA registration support, technical file preparation, or standards interpretation services now face heightened demand for bilingual (Portuguese–English/Chinese) expertise. The dual-standard requirement increases complexity in test report validation and declaration of conformity drafting—especially where GB 9706.1-2020 alignment with IEC 60601-1:2012 differs in scope or test methodology.

Distributors and Importers in Brazil

Brazilian importers and distributors of rehab devices may experience faster product onboarding—but only for models explicitly covered under the resolution. They must verify whether their supplier’s product has received authorization under RDC No. 45/2026, as general ANVISA registration remains unchanged for non-eligible categories or non-compliant specifications.

Key Considerations and Practical Responses

Monitor official implementation guidance from ANVISA

Resolution RDC No. 45/2026 is the foundational text, but operational details—such as acceptable formats for GB 9706.1-2020 test reports, translation requirements for Portuguese-language submissions, or definitions of “smart” functionality in walking aids—have not yet been published. Stakeholders should track ANVISA’s official notices and public consultations over the next 60 days.

Confirm eligibility before initiating registration

Only devices meeting both IEC 60601-2-52 and GB 9706.1-2020 apply. Products certified solely to one standard—or to older versions (e.g., GB 9706.1-2007)—do not qualify. Manufacturers and exporters must conduct a gap analysis between current certifications and the two required standards prior to submission.

Distinguish policy signal from operational readiness

The issuance of RDC No. 45/2026 signals regulatory intent, but actual processing speed depends on ANVISA’s internal capacity and workload. Early approvals went to six pre-vetted manufacturers; broader access may require additional administrative steps or updated system configurations at ANVISA. Firms should treat the 45-day timeline as a target—not a guaranteed service level—until further performance data emerges.

Prepare documentation and supply chain coordination early

Eligibility requires full traceability of design, testing, and manufacturing controls across both standards. Exporters should begin compiling bilingual technical files, updating declarations of conformity, and aligning factory audit schedules with third-party CB bodies accredited for both IEC and GB assessments. Coordination with Brazilian legal representatives must begin ahead of submission to avoid delays in power-of-attorney or local address verification.

Editorial Perspective / Industry Observation

Observably, this resolution reflects ANVISA’s increasing willingness to recognize aligned national standards as equivalent to international benchmarks—provided they demonstrate substantive convergence in safety and performance requirements. Analysis shows that RDC No. 45/2026 functions primarily as a targeted facilitation measure, not a broad regulatory reform. It does not relax safety thresholds; rather, it streamlines evaluation where evidence of conformity is already robust and mutually verifiable. From an industry perspective, this is best understood as a pilot signal—testing feasibility of bilateral standard recognition in a high-need, lower-risk device category—rather than an indication of wholesale process overhaul across all medical device classes.

Current more appropriate understanding is that this is a procedural acceleration for a narrowly defined subset of products, contingent on strict dual-standard adherence. Its scalability to other device types or jurisdictions remains unconfirmed and would require separate regulatory action.

This initiative matters less as a standalone policy shift and more as an indicator of how regulatory convergence—when anchored in verifiable technical alignment—can translate into tangible time savings for compliant manufacturers. For stakeholders, sustained attention should focus on whether similar pathways emerge for adjacent categories (e.g., home-use TENS units or pressure-relieving mattresses), and how ANVISA evaluates real-world adherence post-authorization.

Conclusion: The fast-track for Chinese rehab devices marks a pragmatic, standards-based adjustment—not a paradigm shift—in Brazil’s medical device regulation. It offers measurable efficiency gains for a specific, well-defined cohort of exporters and manufacturers, but its broader applicability remains conditional and unproven. Stakeholders are advised to treat it as an opportunity requiring precise technical execution—not a generalized easing of market access requirements.

Information Source: Official text of ANVISA Resolution RDC No. 45/2026, published May 7, 2026. Ongoing monitoring is recommended for supplementary guidance documents, which have not yet been released as of the date of this article.